Sickle Cell Disease Clinical Trial
Official title:
The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2
NCT number | NCT01123863 |
Other study ID # | BRAIN2 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 2010 |
Est. completion date | May 2015 |
Verified date | June 2015 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A preliminary study was conducted involving 88 three-year-old children with sickle cell
disease (SCD) who were followed at the St. Jude Children's Research Hospital Sickle Cell
Center. They were offered developmental screening with the Brigance Preschool Screen-II test
during their regular clinic visits from January 2006 to August 2008. Data from this work
showed that 50% of 3 year old children with SCD had low developmental screening scores. In
addition, the low scores were found to be associated with less parental education and with
speech deficits. However they were not associated with sickle cell genotype and hemoglobin
level.
The primary goal of this study is to prospectively administer Brigance Preschool Screen -II
to 3 year old children with SCD and 3 year old children without SCD who come from similar
socioeconomic backgrounds and compare the results between the two groups.
Status | Completed |
Enrollment | 248 |
Est. completion date | May 2015 |
Est. primary completion date | May 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 3 Years to 4 Years |
Eligibility |
PATIENT GROUP Inclusion criteria: - 3.0-<4.0 years of age - African-American - Diagnosis of sickle cell disease (HbSS, HbSC, HbSߺthalassemia, HbSß^+thalassemia) - Followed at St. Jude Children's Research Hospital Sickle Cell Center Exclusion criteria: - Previous stroke - Patients who are currently on a chronic transfusion program - Known diagnosis associated with significant cognitive impairment (e.g. Down syndrome, mental retardation) - Previously tested with Brigance Preschool Screen-II CONTROL GROUP Inclusion criteria: - 3.0-<4.0 years of age - African-American - Attendee of day-care in Memphis area Exclusion criteria: 1. Known diagnosis associated with significant cognitive impairment (e.g. stroke, Down syndrome, mental retardation) 2. Known diagnosis sickle cell disease (HbSS, HbSC, HbSߺthalassemia, HbSß^+thalassemia) 3. Previously tested with Brigance Preschool Screen-II |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Compare development in 3 year old children with SCD who are not on treatment to age matched controls using pass/fail rate for the Brigance Preschool Screen II. | 4 years | ||
Secondary | Compare the raw scores of the Brigance Preschool Screen II between SCD and control groups. | 4 years | ||
Secondary | Compare the pass/fail rate and the raw scores between SCD patients who are not on any treatment and those who are being treated with hydroxyurea. | 4 years | ||
Secondary | Compare the pass/fail rate and the raw scores between SCD patients on hydroxyurea treatment and the healthy controls | 4 years | ||
Secondary | Assess the influence of medical factors on the Brigance Preschool Screen II performance in children with SCD. | 4 years | ||
Secondary | Assess the influence of socioeconomic factors on the Brigance Preschool II results in children with SCD and controls. | 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 |